Market Overview

UPDATE: Wedbush Reduces PT to $56 on Centene on Industry-Wide Earnings, Growth Volatility

Related CNC
UBS Says Centene Faces No Weakness In Fundamentals, Despite Shakiness In Shares
Mid-Afternoon Market Update: Gold Futures Up 2%; CoLucid Shares Climb After Migraine Drug Achieves Primary And Key Secondary Endpoints
ObamaCare Is Ill But Hasn't Entered Death Spiral (Investor's Business Daily)

Wedbush reiterates its Outperform rating on Centene (NYSE: CNC) and reduces its price target from $52 to $36.

Wedbush comments, "We believe dual, ABD, and LTC contracts will be profitable in Y2 and beyond; reiterate OUTPERFORM, but now see higher risk for margin volatility in Y1 - as such, we are lowering our Medicaid multiple to 11.7x from 17.2x and our price target to $36. We still see significant top-line growth potential over the next few years as over $300B in contracts are awarded."

CNC closed at $26.84 on Thursday.

Latest Ratings for CNC

Oct 2016Credit SuisseMaintainsOutperform
Sep 2016Evercore ISI GroupInitiates Coverage onBuy
Sep 2016Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (CNC)

View Comments and Join the Discussion!